Literature DB >> 25708009

Advances in pathology of diabetes from pancreatic islets to neuropathy--a tribute to Paul Langerhans.

Soroku Yagihashi1.   

Abstract

There emerges a world epidemic of diabetes, afflicting over 3.8 billion people globally. The socio-economic burden of this disorder is tremendous and there is an urgent need to solve the problems incurred from this disorder and to establish an efficient way of prevention and treatment. Fundamental pathology of diabetes has been too diverse to reach a simple etiology and the mechanisms of how the lesions specific to diabetes develop are yet to be clear. Nevertheless, there has been slow but significant advancement in the understanding of the disease based on characterization of the salient features of pathological lesions in human diabetic subjects. Progressive decline of islet β cells associated with increased α cell volume density was found to account for clinical manifestation of hypoinsulinemia and hyperglucagonemia in type 2 diabetes. Concurrently, signs of complications represented by distal nerve fiber loss in the skin commences from the beginning of this disease. Thus the pathological studies disclosed the major attributes in this disorder targeting the islet of pancreas and epidermal nerve, both of which were discovered by Paul Langerhans more than 140 years ago. In this review, I attempt to summarize the progress in pathology of diabetes which Langerhans opened this field.
© 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Langerhans; islets; neuropathy; type 2 diabetes

Mesh:

Year:  2015        PMID: 25708009     DOI: 10.1111/pin.12263

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  1 in total

1.  Biochemical and Behavioral Consequences of Ethanol Intake in a Mouse Model of Metabolic Syndrome.

Authors:  Pablo Baliño; Ricard Romero-Cano; María Muriach
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.